Scholarlink

<p><i>NTRK</i> gene fusions serve as oncogenic drivers in solid tumors. While these fusions are uncommon in prostate cancer, they can be detected through cancer genome profiling tests. In a study of 68 prostate cancer cases analyzed with comprehensive cancer genome profiling, we identified a single instance of a novel <i>EFNA1–NTRK1</i> fusion. The patient, a 56-year-old male diagnosed with prostate cancer and bone metastasis, presented with an initial PSA level of 323&#xa0;ng/mL, a Gleason score of 4 + 4, and was classified as cT3bN0M1b. He underwent combined androgen blockade therapy but progressed to castration-resistant prostate cancer after 31&#xa0;months. Despite previous treatments with androgen receptor signaling inhibitors and chemotherapies, the cancer continued to advance. Following the identification of an <i>EFNA1–NTRK1</i> gene fusion via a cancer genome profiling test, the patient received treatment with larotrectinib. Although the initial biopsy showed positive pan-TRK staining in the prostate cancer tissue, the response to larotrectinib was limited in this case.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1–NTRK1 fusion gene

  • 期刊论文

  • 发表日期：

    2025年5月9日

查看全文
  • Tomohiro Kanaki,
  • Koji Hatano,
  • Shinichiro Tahara,
  • Yu Ishizuya,
  • Takuji Hayashi,
  • Yoshiyuki Yamamoto,
  • Taigo Kato,
  • Atsunari Kawashima,
  • Tsuyoshi Takada,
  • Norio Nonomura

摘要

NTRK gene fusions serve as oncogenic drivers in solid tumors. While these fusions are uncommon in prostate cancer, they can be detected through cancer genome profiling tests. In a study of 68 prostate cancer cases analyzed with comprehensive cancer genome profiling, we identified a single instance of a novel EFNA1–NTRK1 fusion. The patient, a 56-year-old male diagnosed with prostate cancer and bone metastasis, presented with an initial PSA level of 323 ng/mL, a Gleason score of 4 + 4, and was classified as cT3bN0M1b. He underwent combined androgen blockade therapy but progressed to castration-resistant prostate cancer after 31 months. Despite previous treatments with androgen receptor signaling inhibitors and chemotherapies, the cancer continued to advance. Following the identification of an EFNA1–NTRK1 gene fusion via a cancer genome profiling test, the patient received treatment with larotrectinib. Although the initial biopsy showed positive pan-TRK staining in the prostate cancer tissue, the response to larotrectinib was limited in this case.